盤中異動 | 愛康醫療盤中上漲8%,報於7.42港元
2022年10月14日11時13分,愛康醫療(HK01789)盤中上漲8%,報於7.42港元,成交額達1559.2萬港元,換手率達到0.17%。
8月30日訊,愛康醫療(01789)發佈2022年中期業績,收入5.31億元(人民幣,下同),同比增長18.7%;公司權益股東應佔溢利1.26億元,同比增長13.1%;每股基本盈利0.11元。由於自2022年4月起實施全國關節植入物帶量採購,令醫院使用集團品牌產品的關節手術量增加,帶動銷量大幅增加,彌補了該帶量採購導致的價格下降。
9月1日,招銀國際:維持愛康醫療(01789)“買入”評級,目標價升至9.2港元。
最新的財務數據顯示,公司於2022年1季度,營業收入2.66億人民幣,淨利潤0.63億人民幣;營業收入同比增加18.67%,毛利潤同比增加9.8%,淨利潤同比增加13.05%。
盈立趨勢長盈模型最近一次交易信號,2022年10月13日出現觀望信號,觸發價格爲6.87港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.